{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:55:27Z","timestamp":1774608927234,"version":"3.50.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pemphigoid diseases are a group of autoimmune blistering skin diseases defined by an immune response against certain components of the dermal-epidermal adhesion complex. They are prototypical, autoantibody-driven, organ-specific diseases with the emergence of inflammatory skin lesions dependent on the recruitment of immune cells, particularly granulocytes, into the skin. During an acute flare of disease, inflammatory skin lesions typically progressing from erythema through urticarial plaques to subepidermal blisters erosions erupt and, finally, completely resolve, thus illustrating that resolution of inflammation is continuously executed in pemphigoid disease patients and can be directly monitored on the skin. Despite these superb conditions for examining resolution in pemphigoid diseases as paradigm diseases for antibody-induced tissue inflammation, the mechanisms of resolution in pemphigoid are underinvestigated and still largely elusive. In the last decade, mouse models for pemphigoid diseases were developed, which have been instrumental to identify several key pathways for the initiation of inflammation in these diseases. More recently, also protective pathways, specifically IL-10 and C5aR2 signalling on the molecular level and T<jats:sub>regs<\/jats:sub>on the cellular level, counteracting skin inflammation have been highlighted and may contribute to the continuous execution of resolution in pemphigoid diseases. The upstream orchestrators of this process are currently under investigation. Pemphigoid disease patients, particularly bullous pemphigoid patients, who are predominantly above 75\u00a0years of age, often succumb to the side effects of the immunosuppressive therapeutics nowadays still required to suppress the disease. Pemphigoid disease patients may therefore represent a group of patients benefiting most substantially from the introduction of non-immunosuppressive, proresolving therapeutics into the treatment regimens for their disease.<\/jats:p>","DOI":"10.1007\/s00281-019-00759-y","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T17:02:45Z","timestamp":1573837365000},"page":"645-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Resolution in bullous pemphigoid"],"prefix":"10.1007","volume":"41","author":[{"given":"Christian D.","family":"Sadik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-8913","authenticated-orcid":false,"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"759_CR1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","volume":"8","author":"RJ Ludwig","year":"2017","unstructured":"Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM et al (2017) Mechanisms of autoantibody-induced pathology. Front Immunol 8:603","journal-title":"Front Immunol"},{"issue":"1","key":"759_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","volume":"54","author":"KT Amber","year":"2018","unstructured":"Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L (2018) Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 54(1):26\u201351","journal-title":"Clin Rev Allergy Immunol"},{"key":"759_CR3","first-page":"1","volume-title":"Rook\u2019s textbook of dermatology, part 3, chapter 50","author":"E Schmidt","year":"2016","unstructured":"Schmidt E, Groves R (2016) Immunobullous diseases. In: Griffith C, Barker J, Chalmers BT, Creamer D (eds) Rook\u2019s textbook of dermatology, part 3, chapter 50, vol 50, 9th edn. Wiley-Blackwell, Chichester, pp 1\u201356","edition":"9"},{"issue":"9863","key":"759_CR4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet. 381(9863):320\u2013332","journal-title":"Lancet."},{"issue":"12","key":"759_CR5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F Hubner","year":"2016","unstructured":"Hubner F, Recke A, Zillikens D, Linder R, Schmidt E (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 136(12):2495\u20132498","journal-title":"J Invest Dermatol"},{"issue":"5","key":"759_CR6","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7(5):434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"759_CR7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","volume":"153","author":"VS Gudi","year":"2005","unstructured":"Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F et al (2005) Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 153(2):424\u2013427","journal-title":"Br J Dermatol"},{"issue":"4","key":"759_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"G Marazza","year":"2009","unstructured":"Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM et al (2009) Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 161(4):861\u2013868","journal-title":"Br J Dermatol"},{"issue":"1","key":"759_CR9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ et al (2014) Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol 71(1):92\u201399","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"759_CR10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S et al (2012) Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 132(8):1998\u20132004","journal-title":"J Invest Dermatol"},{"key":"759_CR11","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J (2008) Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study. BMJ 337:a180","journal-title":"BMJ"},{"issue":"9","key":"759_CR12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","volume":"309","author":"K Thorslund","year":"2017","unstructured":"Thorslund K, Seifert O, Nilzen K, Gronhagen C (2017) Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res 309(9):721\u2013727","journal-title":"Arch Dermatol Res"},{"key":"759_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","volume":"32","author":"WF Lever","year":"1953","unstructured":"Lever WF (1953) Pemphigus. Medicine. 32:1\u2013123","journal-title":"Medicine."},{"issue":"5","key":"759_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346(5):321\u2013327","journal-title":"N Engl J Med"},{"issue":"4","key":"759_CR15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D et al (2015) Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 172(4):867\u2013877","journal-title":"Br J Dermatol"},{"issue":"5","key":"759_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","volume":"16","author":"IS Bagci","year":"2017","unstructured":"Bagci IS, Horvath ON, Ruzicka T, Sardy M (2017) Bullous pemphigoid. Autoimmun Rev 16(5):445\u2013455","journal-title":"Autoimmun Rev"},{"issue":"8","key":"759_CR17","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.157.8.3642","volume":"157","author":"E Delaporte","year":"1996","unstructured":"Delaporte E, Dubost-Brama A, Ghohestani R, Nicolas JF, Neyrinck JL, Bergoend H et al (1996) IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 157(8):3642\u20133647","journal-title":"J Immunol"},{"issue":"1","key":"759_CR18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjd.15114","volume":"177","author":"T Hashimoto","year":"2017","unstructured":"Hashimoto T, Ohzono A, Teye K, Numata S, Hiroyasu S, Tsuruta D et al (2017) Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol 177(1):141\u2013151","journal-title":"Br J Dermatol"},{"issue":"2","key":"759_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","volume":"49","author":"N Ishiura","year":"2008","unstructured":"Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N et al (2008) Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 49(2):153\u2013161","journal-title":"J Dermatol Sci"},{"issue":"3","key":"759_CR20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"S Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E et al (2011) Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131(3):637\u2013643","journal-title":"J Invest Dermatol"},{"issue":"3","key":"759_CR21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"SM Langan","year":"2010","unstructured":"Langan SM, Groves RW, West J (2010) The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 131(3):631\u2013636","journal-title":"J Invest Dermatol"},{"issue":"11","key":"759_CR22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","volume":"146","author":"K Taghipour","year":"2010","unstructured":"Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F (2010) The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 146(11):1251\u20131254","journal-title":"Arch Dermatol"},{"issue":"12","key":"759_CR23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","volume":"26","author":"AK Forsti","year":"2017","unstructured":"Forsti AK, Huilaja L, Schmidt E, Tasanen K (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26(12):1228\u20131234","journal-title":"Exp Dermatol"},{"issue":"3","key":"759_CR24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","volume":"132","author":"S Bastuji-Garin","year":"1996","unstructured":"Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C et al (1996) Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 132(3):272\u2013276","journal-title":"Arch Dermatol"},{"issue":"1","key":"759_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","volume":"149","author":"A Lloyd-Lavery","year":"2013","unstructured":"Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K (2013) The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 149(1):58\u201362","journal-title":"JAMA Dermatol"},{"key":"759_CR26","doi-asserted-by":"crossref","unstructured":"Kridin K, Cohen AD (2018) Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol","DOI":"10.1016\/j.jaad.2018.09.048"},{"issue":"7","key":"759_CR27","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","volume":"138","author":"O Varpuluoma","year":"2018","unstructured":"Varpuluoma O, Forsti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L et al (2018) Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol 138(7):1659\u20131661","journal-title":"J Invest Dermatol"},{"issue":"6","key":"759_CR28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L (2018) Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol 78(6):1090\u20131096","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"759_CR29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","volume":"29","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, della Torre R, Borradori L (2011) Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 29(3):427\u2013438 viii-ix","journal-title":"Dermatol Clin"},{"issue":"2","key":"759_CR30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","volume":"10","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 10(2):84\u201389","journal-title":"Autoimmun Rev"},{"issue":"23","key":"759_CR31","first-page":"399","volume":"108","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Deutsches Arzteblatt international 108(23):399\u2013405 I-III","journal-title":"Deutsches Arzteblatt international"},{"issue":"5","key":"759_CR32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","volume":"166","author":"IM Blocker","year":"2012","unstructured":"Blocker IM, Dahnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W et al (2012) Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol 166(5):964\u2013970","journal-title":"Br J Dermatol"},{"issue":"9","key":"759_CR33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-0625.2007.00592.x","volume":"16","author":"C Sitaru","year":"2007","unstructured":"Sitaru C, Dahnrich C, Probst C, Komorowski L, Blocker I, Schmidt E et al (2007) Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 16(9):770\u2013777","journal-title":"Exp Dermatol"},{"issue":"3","key":"759_CR34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","volume":"147","author":"J Charneux","year":"2011","unstructured":"Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C et al (2011) Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 147(3):286\u2013291","journal-title":"Arch Dermatol"},{"issue":"7","key":"759_CR35","first-page":"713","volume":"13","author":"E Schmidt","year":"2015","unstructured":"Schmidt E, Goebeler M, Hertl M, Sardy M, Sitaru C, Eming R et al (2015) S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13(7):713\u2013727","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"759_CR36","first-page":"1077","volume":"16","author":"N van Beek","year":"2018","unstructured":"van Beek N, Zillikens D, Schmidt E (2018) Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges 16(9):1077\u20131091","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"759_CR37","first-page":"833","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H et al (2015) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 13(8):833\u2013844","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"759_CR38","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, Glaser R, Hertl M, Pfeiffer C et al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177(5):1299\u20131305","journal-title":"Br J Dermatol"},{"issue":"10079","key":"759_CR39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 389(10079):1630\u20131638","journal-title":"Lancet."},{"issue":"9","key":"759_CR40","first-page":"1109","volume":"16","author":"F Hubner","year":"2018","unstructured":"Hubner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hubner J, Sufke S et al (2018) Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges 16(9):1109\u20131118","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"759_CR41","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","volume":"71","author":"M Kasperkiewicz","year":"2014","unstructured":"Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D et al (2014) Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. J Am Acad Dermatol 71(5):1018\u20131020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"759_CR42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 65(3):552\u2013558","journal-title":"J Am Acad Dermatol"},{"key":"759_CR43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","volume":"9","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horvath B (2018) Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol 9:248","journal-title":"Front Immunol"},{"key":"759_CR44","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","volume":"10","author":"G Genovese","year":"2019","unstructured":"Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV (2019) New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol 10:1506","journal-title":"Front Immunol"},{"issue":"4","key":"759_CR45","first-page":"577","volume":"42","author":"R Dopp","year":"2000","unstructured":"Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D (2000) IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 42(4):577\u2013583","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"759_CR46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","volume":"144","author":"Y Iwata","year":"2008","unstructured":"Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T et al (2008) Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 144(1):41\u201348","journal-title":"Arch Dermatol"},{"issue":"1\u20132","key":"759_CR47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","volume":"346","author":"KA Messingham","year":"2009","unstructured":"Messingham KA, Noe MH, Chapman MA, Giudice GJ, Fairley JA (2009) A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 346(1\u20132):18\u201325","journal-title":"J Immunol Methods"},{"issue":"3","key":"759_CR48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/jaut.2000.0437","volume":"15","author":"A Kromminga","year":"2000","unstructured":"Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E et al (2000) Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 15(3):293\u2013300","journal-title":"J Autoimmun"},{"issue":"2","key":"759_CR49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2133.2000.03661.x","volume":"143","author":"S Christophoridis","year":"2000","unstructured":"Christophoridis S, Budinger L, Borradori L, Hunziker T, Merk HF, Hertl M (2000) IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 143(2):349\u2013355","journal-title":"Br J Dermatol"},{"issue":"1","key":"759_CR50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","volume":"153","author":"N van Beek","year":"2017","unstructured":"van Beek N, Luttmann N, Huebner F, Recke A, Karl I, Schulze FS et al (2017) Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153(1):30\u201338","journal-title":"JAMA Dermatol"},{"issue":"3","key":"759_CR51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","volume":"12","author":"N van Beek","year":"2016","unstructured":"van Beek N, Schulze FS, Zillikens D, Schmidt E (2016) IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol 12(3):267\u2013277","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"759_CR52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clim.2003.12.007","volume":"111","author":"A Kromminga","year":"2004","unstructured":"Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D (2004) Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 111(1):146\u2013152","journal-title":"Clin Immunol"},{"issue":"6","key":"759_CR53","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.0022-202X.2004.22603.x","volume":"122","author":"S Thoma-Uszynski","year":"2004","unstructured":"Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P et al (2004) BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 122(6):1413\u20131422","journal-title":"J Invest Dermatol"},{"issue":"1","key":"759_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdermsci.2005.11.002","volume":"41","author":"M Yoshida","year":"2006","unstructured":"Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K et al (2006) Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 41(1):21\u201330","journal-title":"J Dermatol Sci"},{"key":"759_CR55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.04630.x","volume":"1173","author":"M Tampoia","year":"2009","unstructured":"Tampoia M, Lattanzi V, Zucano A, Villalta D, Filotico R, Fontana A et al (2009) Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci 1173:15\u201320","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"759_CR56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archdermatol.2011.21","volume":"147","author":"A Roussel","year":"2011","unstructured":"Roussel A, Benichou J, Randriamanantany ZA, Gilbert D, Drenovska K, Houivet E et al (2011) Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 147(3):293\u2013298","journal-title":"Arch Dermatol"},{"issue":"5","key":"759_CR57","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI28547","volume":"116","author":"M Hertl","year":"2006","unstructured":"Hertl M, Eming R, Veldman C (2006) T cell control in autoimmune bullous skin disorders. J Clin Invest 116(5):1159\u20131166","journal-title":"J Clin Invest"},{"issue":"3","key":"759_CR58","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","volume":"176","author":"S Thoma-Uszynski","year":"2006","unstructured":"Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M (2006) Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 176(3):2015\u20132023","journal-title":"J Immunol"},{"issue":"12","key":"759_CR59","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI3335","volume":"102","author":"L Budinger","year":"1998","unstructured":"Budinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H et al (1998) Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102(12):2082\u20132089","journal-title":"J Clin Invest"},{"issue":"6","key":"759_CR60","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1046\/j.1523-1747.2000.00153.x","volume":"115","author":"MS Lin","year":"2000","unstructured":"Lin MS, Fu CL, Giudice GJ, Olague-Marchan M, Lazaro AM, Stastny P et al (2000) Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 115(6):955\u2013961","journal-title":"J Invest Dermatol"},{"issue":"1","key":"759_CR61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0625.2006.00522.x","volume":"16","author":"A Rensing-Ehl","year":"2007","unstructured":"Rensing-Ehl A, Gaus B, Bruckner-Tuderman L, Martin SF (2007) Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Exp Dermatol 16(1):13\u201321","journal-title":"Exp Dermatol"},{"issue":"11","key":"759_CR62","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1600-0625.2009.00875.x","volume":"18","author":"E Oswald","year":"2009","unstructured":"Oswald E, Fisch P, Jakob T, Bruckner-Tuderman L, Martin SF, Rensing-Ehl A (2009) Reduced numbers of circulating gammadelta T cells in patients with bullous pemphigoid. Exp Dermatol 18(11):991\u2013993","journal-title":"Exp Dermatol"},{"key":"759_CR63","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","volume":"142","author":"S Haeberle","year":"2018","unstructured":"Haeberle S, Wei X, Bieber K, Goletz S, Ludwig RJ, Schmidt E et al (2018) Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. J Allergy Clin Immunol 142:1831\u20131842.e7","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"759_CR64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","volume":"142","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu K, Ujiie H, Kobayashi I, Nishie W, Izumi K, Ito T et al (2018) Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects. J Allergy Clin Immunol 142(6):1818\u201330 e6","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"759_CR65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Brocker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136(2):174\u2013178","journal-title":"Arch Dermatol"},{"issue":"3","key":"759_CR66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","volume":"37","author":"Y Tsuji-Abe","year":"2005","unstructured":"Tsuji-Abe Y, Akiyama M, Yamanaka Y, Kikuchi T, Sato-Matsumura KC, Shimizu H (2005) Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 37(3):145\u2013149","journal-title":"J Dermatol Sci"},{"issue":"3","key":"759_CR67","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","volume":"30","author":"M Kobayashi","year":"2002","unstructured":"Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K et al (2002) BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 30(3):224\u2013232","journal-title":"J Dermatol Sci"},{"issue":"3","key":"759_CR68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-4632.2008.03473.x","volume":"47","author":"S Feng","year":"2008","unstructured":"Feng S, Wu Q, Jin P, Lin L, Zhou W, Sang H et al (2008) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Int J Dermatol 47(3):225\u2013228","journal-title":"Int J Dermatol"},{"issue":"3","key":"759_CR69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","volume":"128","author":"G Di Zenzo","year":"2008","unstructured":"Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T et al (2008) Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 128(3):415\u2013426","journal-title":"Clin Immunol"},{"issue":"1","key":"759_CR70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0923-1811(00)00149-3","volume":"26","author":"Y Amo","year":"2001","unstructured":"Amo Y, Ohkawa T, Tatsuta M, Hamada Y, Fujimura T, Katsuoka K et al (2001) Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 26(1):14\u201318","journal-title":"J Dermatol Sci"},{"issue":"4","key":"759_CR71","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","volume":"118","author":"C Sitaru","year":"2002","unstructured":"Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D (2002) Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 118(4):664\u2013671","journal-title":"J Invest Dermatol"},{"issue":"1","key":"759_CR72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4049\/jimmunol.1001753","volume":"187","author":"KN Messingham","year":"2011","unstructured":"Messingham KN, Srikantha R, DeGueme AM, Fairley JA (2011) FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol 187(1):553\u2013560","journal-title":"J Immunol"},{"issue":"5","key":"759_CR73","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92(5):2480\u20132488","journal-title":"J Clin Invest"},{"issue":"3","key":"759_CR74","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm1496","volume":"13","author":"W Nishie","year":"2007","unstructured":"Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR et al (2007) Humanization of autoantigen. Nat Med 13(3):378\u2013383","journal-title":"Nat Med"},{"issue":"8","key":"759_CR75","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","volume":"184","author":"FS Schulze","year":"2014","unstructured":"Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Kohl J et al (2014) Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol 184(8):2185\u20132196","journal-title":"Am J Pathol"},{"issue":"5","key":"759_CR76","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.4049\/jimmunol.177.5.3461","volume":"177","author":"C Sitaru","year":"2006","unstructured":"Sitaru C, Chiriac MT, Mihai S, Buning J, Gebert A, Ishiko A et al (2006) Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 177(5):3461\u20133468","journal-title":"J Immunol"},{"issue":"4","key":"759_CR77","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","volume":"115","author":"C Sitaru","year":"2005","unstructured":"Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B et al (2005) Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115(4):870\u2013878","journal-title":"J Clin Invest"},{"issue":"1","key":"759_CR78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/JID.2015.356","volume":"136","author":"M Kasperkiewicz","year":"2016","unstructured":"Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E et al (2016) Epidermolysis bullosa Acquisita: from pathophysiology to novel therapeutic options. J Invest Dermatol 136(1):24\u201333","journal-title":"J Invest Dermatol"},{"key":"759_CR79","doi-asserted-by":"crossref","first-page":"812029","DOI":"10.1155\/2013\/812029","volume":"2013","author":"RJ Ludwig","year":"2013","unstructured":"Ludwig RJ (2013) Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol 2013:812029","journal-title":"ISRN Dermatol"},{"key":"759_CR80","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/exd.13415","volume":"26","author":"K Bieber","year":"2017","unstructured":"Bieber K, Koga H, Nishie W (2017) In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases. Exp Dermatol 26:1163\u20131170","journal-title":"Exp Dermatol"},{"key":"759_CR81","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Li L, Xia Y (2017) BP180 is critical in the autoimmunity of bullous pemphigoid. Front Immunol 8:1752","journal-title":"Front Immunol"},{"issue":"5","key":"759_CR82","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","volume":"115","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP et al (2000) Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 115(5):842\u2013848","journal-title":"J Invest Dermatol"},{"issue":"4","key":"759_CR83","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/jid.2008.305","volume":"129","author":"H Iwata","year":"2009","unstructured":"Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K et al (2009) IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 129(4):919\u2013926","journal-title":"J Invest Dermatol"},{"issue":"3","key":"759_CR84","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","volume":"182","author":"S Hiroyasu","year":"2013","unstructured":"Hiroyasu S, Ozawa T, Kobayashi H, Ishii M, Aoyama Y, Kitajima Y et al (2013) Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway. Am J Pathol 182(3):828\u2013840","journal-title":"Am J Pathol"},{"issue":"1","key":"759_CR85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.1998.02028.x","volume":"138","author":"Y Kitajima","year":"1998","unstructured":"Kitajima Y, Nojiri M, Yamada T, Hirako Y, Owaribe K (1998) Internalization of the 180 kDa bullous pemphigoid antigen as immune complexes in basal keratinocytes: an important early event in blister formation in bullous pemphigoid. Br J Dermatol 138(1):71\u201376","journal-title":"Br J Dermatol"},{"issue":"5","key":"759_CR86","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jid.2015.11.030","volume":"136","author":"M Wada","year":"2016","unstructured":"Wada M, Nishie W, Ujiie H, Izumi K, Iwata H, Natsuga K, Nakamura H, Kitagawa Y, Shimizu H (2016) Epitope-dependent pathogenicity of antibodies targeting a major bullous pemphigoid autoantigen collagen XVII\/BP180. J Invest Dermatol 136(5):938\u2013946","journal-title":"J Invest Dermatol"},{"issue":"12","key":"759_CR87","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/labinvest.2016.108","volume":"96","author":"H Iwata","year":"2016","unstructured":"Iwata H, Kamaguchi M, Ujiie H, Nishimura M, Izumi K, Natsuga K et al (2016) Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C. Lab Investig 96(12):1301\u20131310","journal-title":"Lab Investig"},{"issue":"4","key":"759_CR88","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","volume":"95","author":"Z Liu","year":"1995","unstructured":"Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL et al (1995) The role of complement in experimental bullous pemphigoid. J Clin Invest 95(4):1539\u20131544","journal-title":"J Clin Invest"},{"issue":"11","key":"759_CR89","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1172\/JCI17891","volume":"116","author":"KC Nelson","year":"2006","unstructured":"Nelson KC, Zhao M, Schroeder PR, Li N, Wetsel RA, Diaz LA et al (2006) Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest 116(11):2892\u20132900","journal-title":"J Clin Invest"},{"issue":"7","key":"759_CR90","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.4049\/jimmunol.169.7.3987","volume":"169","author":"R Chen","year":"2002","unstructured":"Chen R, Fairley JA, Zhao ML, Giudice GJ, Zillikens D, Diaz LA et al (2002) Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 169(7):3987\u20133992","journal-title":"J Immunol"},{"key":"759_CR91","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","volume":"9","author":"CM Karsten","year":"2018","unstructured":"Karsten CM, Beckmann T, Holtsche MM, Tillmann J, Tofern S, Schulze FS et al (2018) Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol 9:488","journal-title":"Front Immunol"},{"issue":"17","key":"759_CR92","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","volume":"286","author":"L Heimbach","year":"2011","unstructured":"Heimbach L, Li Z, Berkowitz P, Zhao M, Li N, Rubenstein DS et al (2011) The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid. J Biol Chem 286(17):15003\u201315009","journal-title":"J Biol Chem"},{"issue":"9","key":"759_CR93","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.2862","volume":"18","author":"CM Karsten","year":"2012","unstructured":"Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M et al (2012) Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 18(9):1401\u20131406","journal-title":"Nat Med"},{"issue":"10","key":"759_CR94","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.4049\/jimmunol.178.10.6514","volume":"178","author":"S Mihai","year":"2007","unstructured":"Mihai S, Chiriac MT, Takahashi K, Thurman JM, Holers VM, Zillikens D et al (2007) The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 178(10):6514\u20136521","journal-title":"J Immunol"},{"key":"759_CR95","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fimmu.2018.00535","volume":"9","author":"S Mihai","year":"2018","unstructured":"Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP et al (2018) Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Front Immunol 9:535","journal-title":"Front Immunol"},{"issue":"8","key":"759_CR96","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","volume":"137","author":"EN Heppe","year":"2017","unstructured":"Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C et al (2017) Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and Immunopathological characteristics of the human disease. J Invest Dermatol 137(8):1709\u20131718","journal-title":"J Invest Dermatol"},{"issue":"5","key":"759_CR97","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1172\/JCI119639","volume":"100","author":"Z Liu","year":"1997","unstructured":"Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA et al (1997) A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 100(5):1256\u20131263","journal-title":"J Clin Invest"},{"issue":"4","key":"759_CR98","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI23977","volume":"115","author":"Z Liu","year":"2005","unstructured":"Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z (2005) Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 115(4):879\u2013887","journal-title":"J Clin Invest"},{"issue":"1","key":"759_CR99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI3693","volume":"105","author":"Z Liu","year":"2000","unstructured":"Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ et al (2000) A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105(1):113\u2013123","journal-title":"J Clin Invest"},{"issue":"3","key":"759_CR100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.188.3.475","volume":"188","author":"Z Liu","year":"1998","unstructured":"Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z et al (1998) Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 188(3):475\u2013482","journal-title":"J Exp Med"},{"issue":"5","key":"759_CR101","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0092-8674(00)00087-8","volume":"102","author":"Z Liu","year":"2000","unstructured":"Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA et al (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B\/MMP-9 in vivo. Cell. 102(5):647\u2013655","journal-title":"Cell."},{"issue":"5","key":"759_CR102","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2018","unstructured":"Lin L, Hwang BJ, Culton DA, Li N, Burette S, Koller BH et al (2018) Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol 138(5):1032\u20131043","journal-title":"J Invest Dermatol"},{"issue":"5","key":"759_CR103","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","volume":"137","author":"T Sezin","year":"2017","unstructured":"Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K et al (2017) The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. J Invest Dermatol 137(5):1104\u20131113","journal-title":"J Invest Dermatol"},{"key":"759_CR104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","volume":"37","author":"CD Sadik","year":"2018","unstructured":"Sadik CD, Miyabe Y, Sezin T, Luster AD (2018) The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin Immunol 37:21\u201329","journal-title":"Semin Immunol"},{"key":"759_CR105","doi-asserted-by":"crossref","unstructured":"Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM et al (2019) Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight 4(15)","DOI":"10.1172\/jci.insight.128239"},{"issue":"46","key":"759_CR106","doi-asserted-by":"crossref","first-page":"E3177","DOI":"10.1073\/pnas.1213797109","volume":"109","author":"CD Sadik","year":"2012","unstructured":"Sadik CD, Kim ND, Iwakura Y, Luster AD (2012) Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcgammaR signaling. Proc Natl Acad Sci U S A 109(46):E3177\u2013E3185","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"759_CR107","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.it.2011.06.008","volume":"32","author":"CD Sadik","year":"2011","unstructured":"Sadik CD, Kim ND, Luster AD (2011) Neutrophils cascading their way to inflammation. Trends Immunol 32(10):452\u2013460","journal-title":"Trends Immunol"},{"issue":"2","key":"759_CR108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1189\/jlb.0811402","volume":"91","author":"CD Sadik","year":"2012","unstructured":"Sadik CD, Luster AD (2012) Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J Leukoc Biol 91(2):207\u2013215","journal-title":"J Leukoc Biol"},{"key":"759_CR109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","volume":"96","author":"L Chakievska","year":"2019","unstructured":"Chakievska L, Holtsche MM, Kunstner A, Goletz S, Petersen BS, Thaci D et al (2019) IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 96:104\u2013112","journal-title":"J Autoimmun"},{"issue":"12","key":"759_CR110","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","volume":"134","author":"S Le Jan","year":"2014","unstructured":"Le Jan S, Plee J, Vallerand D, Dupont A, Delanez E, Durlach A et al (2014) Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol 134(12):2908\u20132917","journal-title":"J Invest Dermatol"},{"key":"759_CR111","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/srep18001","volume":"5","author":"J Plee","year":"2015","unstructured":"Plee J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C et al (2015) Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep 5:18001","journal-title":"Sci Rep"},{"key":"759_CR112","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fimmu.2019.00701","volume":"10","author":"D Giusti","year":"2019","unstructured":"Giusti D, Bini E, Terryn C, Didier K, Le Jan S, Gatouillat G et al (2019) NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay. Front Immunol 10:701","journal-title":"Front Immunol"},{"issue":"5","key":"759_CR113","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.1674","volume":"204","author":"I Shimanovich","year":"2004","unstructured":"Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Brocker EB, Opdenakker G et al (2004) Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 204(5):519\u2013527","journal-title":"J Pathol"},{"issue":"12","key":"759_CR114","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1038\/jid.2010.230","volume":"130","author":"X Yu","year":"2010","unstructured":"Yu X, Holdorf K, Kasper B, Zillikens D, Ludwig RJ, Petersen F (2010) FcgammaRIIA and FcgammaRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J Invest Dermatol 130(12):2841\u20132844","journal-title":"J Invest Dermatol"},{"issue":"5","key":"759_CR115","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1172\/JCI117196","volume":"93","author":"M Stahle-Backdahl","year":"1994","unstructured":"Stahle-Backdahl M, Inoue M, Guidice GJ, Parks WC (1994) 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 93(5):2022\u20132030","journal-title":"J Clin Invest"},{"issue":"2","key":"759_CR116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000090385","volume":"139","author":"Y Niimi","year":"2006","unstructured":"Niimi Y, Pawankar R, Kawana S (2006) Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 139(2):104\u2013113","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"759_CR117","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","volume":"117","author":"S Verraes","year":"2001","unstructured":"Verraes S, Hornebeck W, Polette M, Borradori L, Bernard P (2001) Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 117(5):1091\u20131096","journal-title":"J Invest Dermatol"},{"issue":"43","key":"759_CR118","doi-asserted-by":"crossref","first-page":"37358","DOI":"10.1074\/jbc.M111.272401","volume":"286","author":"L Lin","year":"2011","unstructured":"Lin L, Bankaitis E, Heimbach L, Li N, Abrink M, Pejler G et al (2011) Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid. J Biol Chem 286(43):37358\u201337367","journal-title":"J Biol Chem"},{"issue":"1","key":"759_CR119","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","volume":"31","author":"L Lin","year":"2012","unstructured":"Lin L, Betsuyaku T, Heimbach L, Li N, Rubenstein D, Shapiro SD et al (2012) Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid. Matrix Biol 31(1):38\u201344","journal-title":"Matrix Biol"},{"issue":"1","key":"759_CR120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2249.2011.04391.x","volume":"165","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M (2011) Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 165(1):44\u201350","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"759_CR121","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1160\/TH15-04-0309","volume":"115","author":"M Cugno","year":"2016","unstructured":"Cugno M, Marzano AV, Bucciarelli P, Balice Y, Cianchini G, Quaglino P et al (2016) Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study. Thromb Haemost 115(1):193\u2013199","journal-title":"Thromb Haemost"},{"issue":"12","key":"759_CR122","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/exd.13367","volume":"26","author":"H Iwata","year":"2017","unstructured":"Iwata H, Ujiie H (2017) Complement-independent blistering mechanisms in bullous pemphigoid. Exp Dermatol 26(12):1235\u20131239","journal-title":"Exp Dermatol"},{"issue":"11","key":"759_CR123","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","volume":"188","author":"K Natsuga","year":"2012","unstructured":"Natsuga K, Nishie W, Shinkuma S, Ujiie H, Nishimura M, Sawamura D et al (2012) Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner. J Immunol 188(11):5792\u20135799","journal-title":"J Immunol"},{"issue":"9","key":"759_CR124","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","volume":"193","author":"H Ujiie","year":"2014","unstructured":"Ujiie H, Sasaoka T, Izumi K, Nishie W, Shinkuma S, Natsuga K et al (2014) Bullous pemphigoid autoantibodies directly induce blister formation without complement activation. J Immunol 193(9):4415\u20134428","journal-title":"J Immunol"},{"issue":"12","key":"759_CR125","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","volume":"202","author":"XX Li","year":"2019","unstructured":"Li XX, Lee JD, Kemper C, Woodruff TM (2019) The complement receptor C5aR2: a powerful modulator of innate and adaptive immunity. J Immunol 202(12):3339\u20133348","journal-title":"J Immunol"},{"issue":"4","key":"759_CR126","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting Interleukin-6 signaling in clinic. Immunity. 50(4):1007\u20131023","journal-title":"Immunity."},{"issue":"2","key":"759_CR127","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","volume":"101","author":"Z Xing","year":"1998","unstructured":"Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF et al (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101(2):311\u2013320","journal-title":"J Clin Invest"},{"issue":"4","key":"759_CR128","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"M Murakami","year":"2019","unstructured":"Murakami M, Kamimura D, Hirano T (2019) Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 50(4):812\u2013831","journal-title":"Immunity."},{"key":"759_CR129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2012.08.002","volume":"40","author":"UK Samavedam","year":"2012","unstructured":"Samavedam UK, Kalies K, Scheller J, Sadeghi H, Gupta Y, Jonkman MF et al (2012) Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 40:74\u201385","journal-title":"J Autoimmun"},{"issue":"7","key":"759_CR130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF02507102","volume":"288","author":"E Schmidt","year":"1996","unstructured":"Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D (1996) Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 288(7):353\u2013357","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"759_CR131","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.4049\/jimmunol.1402688","volume":"194","author":"H Sadeghi","year":"2015","unstructured":"Sadeghi H, Lockmann A, Hund AC, Samavedam UK, Pipi E, Vafia K et al (2015) Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules. J Immunol 194(8):3656\u20133663","journal-title":"J Immunol"},{"key":"759_CR132","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3389\/fimmu.2017.01628","volume":"8","author":"K Bieber","year":"2017","unstructured":"Bieber K, Sun S, Witte M, Kasprick A, Beltsiou F, Behnen M et al (2017) Regulatory T cells suppress inflammation and blistering in pemphigoid diseases. Front Immunol 8:1628","journal-title":"Front Immunol"},{"issue":"2","key":"759_CR133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","volume":"28","author":"E Antiga","year":"2014","unstructured":"Antiga E, Quaglino P, Volpi W, Pierini I, Del Bianco E, Bianchi B et al (2014) Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 28(2):222\u2013230","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"759_CR134","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","volume":"137","author":"U Kulkarni","year":"2016","unstructured":"Kulkarni U, Karsten CM, Kohler T, Hammerschmidt S, Bommert K, Tiburzy B et al (2016) IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol 137(5):1487\u201397 e6","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"759_CR135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2019.01.007","volume":"40","author":"MA Sugimoto","year":"2019","unstructured":"Sugimoto MA, Vago JP, Perretti M, Teixeira MM (2019) Mediators of the resolution of the inflammatory response. Trends Immunol 40(3):212\u2013227","journal-title":"Trends Immunol"},{"issue":"3","key":"759_CR136","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.smim.2015.03.014","volume":"27","author":"SE Headland","year":"2015","unstructured":"Headland SE, Norling LV (2015) The resolution of inflammation: principles and challenges. Semin Immunol 27(3):149\u2013160","journal-title":"Semin Immunol"},{"issue":"7","key":"759_CR137","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.4049\/jimmunol.174.7.4345","volume":"174","author":"GL Bannenberg","year":"2005","unstructured":"Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH et al (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174(7):4345\u20134355","journal-title":"J Immunol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00759-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-019-00759-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-019-00759-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:55:58Z","timestamp":1695430558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-019-00759-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s00281-019-00759-y","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}